Most AI transitions in life sciences fail — not because the technology isn't ready, but because the strategy, the organizational change, and the data foundations are treated as afterthoughts. This framework exists because the industry deserves an honest, experience-led approach.
The Smarter Lab transition (digitization, connectivity, workflow automation) and the AI Lab transition are not sequential — they overlap. But the AI Lab transition has a fundamentally different risk profile: it shifts decision-making authority from humans to algorithms. This is where most labs stall.
An AI transition that focuses only on technology will fail. The harder problems are organizational: changing how decisions are made, who is accountable for AI-assisted outcomes, and how scientists relate to tools that encroach on their professional judgment. Every phase must address three pillars simultaneously: Technology, Organization & Culture, and Data Supply.
The challenge is that these three pillars rarely live under one roof. Strategy consultancies produce roadmaps but cannot build the systems. Technology vendors build platforms but have inherent conflicts of interest when advising on vendor selection. Pure IT firms can deploy infrastructure but lack the domain understanding of how wet lab science actually works — the assay variability, the regulatory constraints, the deeply human dynamics of a research team under pressure. And none of them can tell you what they've seen go wrong at other organizations, because they haven't been through this transition enough times. Getting this right requires a rare combination: deep R&D domain experience, the ability to design and build custom technology, and the independence to give advice that isn't shaped by a vendor relationship.
There is a further complication: AI itself is a moving target. Some capabilities are proven, productized, and ready for regulated environments — classical ML for tabular prediction, NLP for document classification, well-established RAG architectures. Others — multi-step agentic workflows, autonomous decision-making, real-time closed-loop systems — are early-stage, fragile, and changing quarter by quarter. A lab that commits today to a specific AI architecture risks being locked into yesterday's approach within eighteen months. The only defense is technology staging: making deliberate, informed decisions about which AI capabilities to deploy now, which to pilot cautiously, and which to watch from a distance — while designing an architecture that can absorb advances without requiring a full rebuild. This is not a one-time decision. It requires continuous, objective reassessment of what the technology can actually do, separated from what vendors claim it can do.
Most labs today sit between Digital and Informed. The jump to Augmented is where value — and risk — accelerate. Understanding where your lab actually sits on this spectrum, rather than where you assume it sits, is the first step. That assessment requires both technical depth and operational experience in lab environments.
| Level | Decision Authority | Example |
|---|---|---|
| Digital | Human decides, digital records | LIMS entry, electronic notebook |
| Informed | Human decides, ML recommends | Predictive model flags assay drift |
| Augmented | Human approves, LLM drafts | Agent writes protocol deviation report |
| Autonomous | AI decides within bounds | Agent adjusts chromatography parameters mid-run |
Each phase addresses technology, organizational change, and data supply in parallel. The gate metric for each phase must be met before the next phase is credible — regardless of what any vendor's sales team tells you. Importantly, the technology within each phase is staged according to actual AI maturity: proven capabilities are deployed, promising ones are piloted, and early-stage ones are monitored — with an architecture designed to evolve as AI advances.
| Phase | Technology | Organization & Culture | Data Supply | Gate Metric |
|---|---|---|---|---|
|
Phase 0
Data Readiness
|
Structured instrument capture, metadata standardization, ontology mapping | Leadership-sponsored, lab champions, data ownership defined | Audit data loss (30–60%), prospective capture, quality baseline | >90% structured data capture |
|
Phase 1
Predictive Intelligence
|
Assay prediction, drift detection, compound-property ML, DoE optimization | "Trust but verify" posture, ML literacy, accountability framework | Labelled training data, new data streams, external datasets (ChEMBL) | Adoption % predictions actually consulted |
|
Phase 2
Augmented Workflows
|
LLM document drafting, RAG-informed design, NL query, troubleshooting agents | AI authority boundaries, Review Board, output review training | Curated RAG corpus, agent logs, literature access, IP governance | >70% draft acceptance rate |
|
Phase 3
Bounded Autonomy
|
Automated parameters, dynamic scheduling, QC triage, predictive ordering | Delegated authority, role redesign, QA/Regulatory co-design | Real-time feeds, decision logs, external ops data, closed-loop feedback | >95% autonomous decision accuracy |
Click any phase to expand the full breakdown — three pillars, business outcomes, success metrics, and honest assessment. Or download the complete reference document.
Making lab data AI-consumable. Not just digital — structured, contextualised, and queryable. This phase overlaps entirely with the Smarter Labs transition.
This is where 80% of labs are stuck. Most "digital transformation" projects produce data that is technically digital but practically unusable for ML or agents. If your Smarter Lab engagement hasn't solved this, the AI transition cannot start. This phase is the gatekeeper. The organizations that get through it fastest are those that have access to people who have done this before — who know which metadata fields matter, which instrument integrations are worth the effort, and which vendor promises about "seamless data capture" will quietly fall apart at scale.
Some vendors will claim their platforms make data "AI-ready" out of the box. This is rarely true for multi-instrument, multi-assay wet lab environments. The heterogeneity problem is severe.
Deploying ML models that surface predictions, patterns, and anomalies from lab data. Humans retain all decision authority.
The bottleneck is not model capability — it is labelled training data. Scientists will not trust predictions they cannot interrogate. Explainability is not optional.
Many labs will get more value from simple statistical process control and dashboards than from ML models. Don't deploy ML where a control chart would suffice — it erodes trust when the complexity isn't justified. The problem is that nobody selling you ML tools will tell you this. The incentive to recommend ML when simpler methods would suffice is strong, and the only protection is independent judgment from someone whose revenue isn't tied to model complexity.
LLM-based agents that draft, summarize, retrieve, and recommend — but require human sign-off before any action is taken.
This is where the gap between demo and production is widest. LLM agents are catastrophically unreliable when exposed to messy lab data, ambiguous SOPs, and exception-heavy workflows. Hallucination in a scientific context is a data integrity risk. Every agent output touching a regulated process must be verifiable. Closing this gap requires people who can both architect the AI system and understand the science it operates on — buying an off-the-shelf agent platform and hoping it works with your data is how most Phase 2 projects fail.
The "human in the loop" framing gives false comfort. In practice, approval fatigue sets in quickly — scientists will rubber-stamp agent outputs they don't fully review. The governance model must account for this.
AI systems that make and execute decisions within pre-defined boundaries, without requiring per-decision human approval. Narrow scope only.
Most wet labs will not — and should not — reach this phase for years. The labs most likely to adopt bounded autonomy first are high-throughput screening and PAT environments where the decision space is well-defined and the feedback loop is fast. For discovery biology, Phase 2 with human oversight is the realistic ceiling for the medium term. The governance frameworks required here — the guardrail design, the audit architecture, the regulatory defensibility — cannot be bolted on after deployment. They must be co-designed with the technology from the outset, by people who understand both the AI systems and the regulatory expectations they must satisfy.
Competitor pressure from AI-native biotechs may force faster adoption than traditional pharma risk frameworks would normally allow. Worth monitoring — but not worth betting a quality system on.
Surveys are not one-off activities. They form a measurement program that tracks organizational readiness and surfaces resistance before it stalls deployment. Leadership must commit to acting visibly on findings — surveys that disappear into a void produce declining response rates and dishonest answers.
| Survey | Deployed At | Frequency | Purpose |
|---|---|---|---|
| Data Practices & Attitudes | Phase 0 baseline | Annually | Track data culture maturity and scientist burden |
| AI Readiness & Trust | Phase 1 entry | Quarterly | Monitor trust, autonomy concerns, ML literacy |
| Workflow Impact & Autonomy | Phase 2 entry | Quarterly | Detect approval fatigue, role anxiety, adoption barriers |
| Post-Autonomy Impact | Phase 3 post-deploy | Per use case + quarterly | Confidence, safety perception, role evolution |
Every ML model and LLM agent operating on regulated data needs a validation protocol proportionate to its decision authority. Model drift monitoring is non-negotiable. Audit trails must extend to AI recommendations, not just human actions. Designing these protocols requires understanding both the technology and the regulatory context — a combination that is rare and cannot be improvised during an inspection.
AI does not relax ALCOA+ requirements — it intensifies them. Every AI-generated data point must be attributable, traceable, and distinguishable from human-generated data. The full provenance chain (model, version, input data, prompt) must be recorded. Organizations that have been through previous data integrity transformations will recognize the pattern; those that haven't will underestimate the effort significantly.
Scientists must understand what AI systems are doing and why — not just what they output. Training must focus on critical evaluation of AI outputs. Job displacement concerns must be addressed honestly — some roles will change significantly. These are not problems a technology deployment can solve. They require people who have navigated this kind of organizational change before, across multiple companies, and who understand how resistance manifests differently in a 20-person biotech versus a 5,000-person pharma R&D division.
Most LIMS/ELN vendors are bolting LLM features onto legacy architectures. "AI-powered" in vendor marketing usually means keyword search with an LLM wrapper. Evaluating these claims objectively is nearly impossible from inside a sales cycle — it requires independent technical assessment by people who understand both the vendor landscape and the lab's actual workflow requirements. Prefer platforms with open APIs and data export over proprietary AI features you cannot validate.
Not all AI is created equal. Classical ML for tabular prediction is proven and productized. RAG-based document retrieval is maturing rapidly. Multi-step agentic workflows remain fragile and unpredictable in production. Autonomous closed-loop systems are early-stage research for most lab contexts. Treating these as a single category called "AI" leads to architectures that over-commit to immature capabilities and under-invest in proven ones. The right approach is technology staging: deploying what is ready now, piloting what is promising, and designing systems with enough modularity to absorb advances — in model capability, in tooling, in cost — without requiring a full rebuild every time the landscape shifts. This demands ongoing, objective assessment of AI maturity that is independent of any vendor's release cycle.
Most consultancies sell AI capabilities to labs that haven't finished digitizing their data. Most vendors sell "AI-powered" platforms that are keyword search with an LLM wrapper. We operate differently — because we've done this before, at scale, for decades.
20/15 Visioneers is a strategy and IT consultancy. We have experts who understand the challenges and the journey — and who can design and build custom technologies and processes to address them. We don't stop at the PowerPoint: we deliver working systems, validated workflows, and the organizational change management required to make them stick. Critically, we understand that AI is not a single, stable technology — it is a rapidly evolving landscape where some capabilities are proven and others are fragile. Our approach to technology staging means we help you deploy what is ready now, pilot what is maturing, and architect systems with enough modularity to absorb future advances without starting over. From initial assessment through deployment and ongoing adaptation, we are with you at every step.
We are deeply integrated into the lab technology vendor ecosystem — LIMS, ELN, instrument, and AI platform providers. This means we can support objective evaluations and selections, ensuring you choose vendors based on fit rather than sales pressure. We have no allegiance to any single platform, which means our recommendations are driven by what works in your environment, not by partnership agreements.
This is not our first transition. We have decades of experience guiding small to large R&D companies through lab automation, data management, and digital transformation. We've seen what works, what fails, and what gets quietly abandoned six months after go-live. That pattern recognition — across organizations of every size, in every stage of maturity — is what makes our phased framework credible rather than theoretical.
We will tell you when a control chart is better than an ML model. We will tell you when your data isn't ready. We will tell you when "human in the loop" is providing false comfort. Honest phasing protects your investment and your quality system. Failed AI projects are expensive and trust-destroying — realistic delivery is the only sustainable approach.
Honest phasing may not be what the market rewards in the short term. Labs under competitive pressure may prefer vendors who promise faster AI adoption, even when the foundation isn't there. The counter-argument: failed AI projects cost more than delayed ones, in money, in trust, and in regulatory credibility. Our track record of realistic delivery is the differentiator — and the moat.
Most labs overestimate their AI readiness and underestimate their data gaps. Our assessment gives you an honest, structured view of where you are today — across all three pillars — so you can plan your next move with confidence, not assumptions.
Or email directly
